Connect with others who understand.

  • Learn from expert-reviewed resources
  • Real advice from people who’ve been there
  • People who understand what you’re going through
Sign Up Log In
Powered By
Real members of MyMSTeam have posted questions and answers that support our community guidelines, and should not be taken as medical advice. Looking for the latest medically reviewed content by doctors and experts? Visit our resource section.
February 23
 · 
Reactions
A MyMSTeam Member

See @A MyMSTeam Member s post about this. Many have had this and many haven't. It is likely one of the triggers that starts the d,isease but likely not the only trigger

February 23
MyMSTeam

How does Epstein-Barr virus (EBV) relate to MS development?

Your experience aligns with what researchers have discovered about the connection between EBV and MS. Studies show it typically takes around 10 years to develop MS symptoms after an EBV infection, which matches your timeline exactly.

EBV is now believed to be a Show Full Answer

How does Epstein-Barr virus (EBV) relate to MS development?

Your experience aligns with what researchers have discovered about the connection between EBV and MS. Studies show it typically takes around 10 years to develop MS symptoms after an EBV infection, which matches your timeline exactly.

EBV is now believed to be a leading cause of MS. The virus becomes dormant in B cells (immune cells) and can collect in the brain. These infected cells attract other immune cells that create inflammation and damage the central nervous system. However, this only happens in people with certain genetic risk factors.

It's important to know that while over 90% of adults worldwide have been infected with EBV, less than 0.04% of the population develops MS. This means EBV infection alone doesn't cause MS—it requires a combination of genetic factors and other environmental triggers.

Current and future treatment options:

The good news is that understanding this EBV-MS connection is opening doors for better treatments. Ocrevus (ocrelizumab), which reduces B cells, has shown significant success in slowing MS progression. Researchers are also exploring EBV-specific T-cell therapy, which showed clinical improvements in early trials.

Scientists believe that preventing EBV infection or targeting it with EBV-specific antiviral drugs could ultimately lead to preventing or even curing MS. While we're not there yet, this research direction is promising for better outcomes.

February 23

Related Questions

View All
A MyMSTeam Member asked a question 💭
Chalk River